The amount of growing appreciation of similarities between vitiligo (autoimmunity) and melanoma (tumor immunity), has indicated the PD-1/PD-L1 axis as a promising target for future immunotherapies in human vitiligo [50]. The gene discussed is CD274; the disease is neoplasm.